Health Care • Biotechnology: Pharmaceutical Preparations
$6.64 ▲ +0.56
(+9.21%)
MKT CAP: $2.38B • VOL: 7.74M
52W L $3 52W H $9
ROARABLE / RQD
D- • 35/100
PIOTROSKI
3 / 9
PGEN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $9.7M | $3.9M | $6.2M |
| YoY Revenue Growth % | +146.7% | -36.9% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$110.5M | -$135.0M | -$99.8M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$250.6M | -$126.2M | -$95.9M |
| EBITDA (Normalized) | -$108.9M | -$128.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$87.8M | -$68.2M | -$66.9M |
| Capital Expenditures (CapEx) | $2.0M | $8.6M | — |
| Free Cash Flow (FCF) | -$89.8M | -$76.8M | -$66.9M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $30.2M | $29.5M | — |
| Total Debt (Short + Long Term) | $93.2M | $0 | — |
| Total Stockholders' Equity | $20.9M | $38.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PGEN.